Clinical Follow-Up of Prostatic Cancer Patients under Intermittent Treatment with Fosfestrol and Bromocriptine

Publisher Website
Google Scholar
Abstract
A clinical follow-up is presented of 152 patients with newly diagnosed prostatic cancer, confirmed histopathologically and intermittently treated with Fosfestrol and bromocriptine in the last few years. The optimal dosage of Fosfestrol and bromocriptine was established on the basis of serum testosterone and prolactin levels. The reduction of Fosfestrol dosage combined with bromocriptine and the intermittent administration of estrogens resulted in a prolongation of the period of sensitivity to female hormones, in a better tolerance for the drugs, and in a reduced number of side effects.

This publication has 0 references indexed in Scilit: